Eiropas Savienība - latviešu - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - idecabtagene vicleucel - multiple myeloma; neoplasms; cancer; neoplasms, plasma cell; hemostatic disorders; vascular diseases; cardiovascular diseases; paraproteinemias; blood protein disorders; hematologic diseases; hemic and lymphatic diseases; hemorrhagic disorders; infectious mononucleosis; lymphoproliferative disorders; immunoproliferative disorders; immune system diseases - antineoplastiski līdzekļi - abecma is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti cd38 antibody and have demonstrated disease progression on the last therapy.

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

teva pharma b.v. - budesonide, formoterol - astma - zāles obstruktīvu elpceļu slimību, - budesonide / formoterol teva pharma b. ir indicēts tikai pieaugušajiem no 18 gadu vecuma. asthmabudesonide/formoterol teva pharma b. is indicated in the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting β2 adrenoceptor agonist) is appropriate: orin patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting β2 adrenoceptor agonists. in patients already adequately controlled on both inhaled corticosteroids and long-acting β2 adrenoceptor agonists.

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

janssen-cilag international nv - canagliflozin - cukura diabēts, 2. tips - cukura diabēts - invokana is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise:as monotherapy when metformin is considered inappropriate due to intolerance or contraindicationsin addition to other medicinal products for the treatment of diabetes. for study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4. 4, 4. 5 un 5.

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

viiv healthcare bv - dolutegravir - hiv infekcijas - pretvīrusu līdzekļi sistēmiskai lietošanai - tivicay is indicated in combination with other anti-retroviral medicinal products for the treatment of human immunodeficiency virus (hiv) infected adults, adolescents and children of at least 6 years of age or older and weighing at least 14 kg. tivicay is indicated in combination with other anti-retroviral medicinal products for the treatment of human immunodeficiency virus (hiv) infected adults, adolescents and children of at least 4 weeks of age or older and weighing at least 3 kg.

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

janssen-cilag international n.v. - darunavir, cobicistat - hiv infekcijas - antivirals for systemic use, antivirals for treatment of hiv infections, combinations - rezolsta ir indicēts kombinācijā ar citām pretretrovīrusu zālēm cilvēka imūndeficīta vīrusa (hiv 1) infekcijas ārstēšanai pieaugušajiem no 18 gadu vecuma. genotypic testēšana būtu ceļvedis, lietošanas rezolsta.

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

janssen-cilag international nv - guselkumabs - psoriāze - imūnsupresanti - plaque psoriasis tremfya is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. psoriatic arthritis tremfya, alone or in combination with methotrexate (mtx), is indicated for the treatment of active psoriatic arthritis in adult patients who have had an inadequate response or who have been intolerant to a prior disease-modifying antirheumatic drug (dmard) therapy (see section 5.

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

janssen-cilag international n.v.    - recombinant modified vaccinia ankara bavarian nordic virus encoding the: ebola virus zaire (zebov) mayinga strain glycoprotein (gp); ebola virus sudan gulu strain gp; ebola virus taï forest strain nucleoprotein and the marburg virus musoke strain gp - hemorāģisko drudzi, ebola - vakcīnas - active immunization for prevention of disease caused by ebola virus (zaire ebolavirus species) in individuals ≥ 1 year of age.

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

janssen-cilag international n.v.    - amivantamab - karcinoma, nesīkšūnu plaušas - antineoplastiski līdzekļi - rybrevant as monotherapy is indicated for treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with activating epidermal growth factor receptor (egfr) exon 20 insertion mutations, after failure of platinum-based chemotherapy.

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

accord healthcare s.l.u. - tolvaptāns - nepiemērots adh sindroms - diurētiskie līdzekļi, - tolvaptan is indicated in adults for the treatment of hyponatremia secondary to the syndrome of inappropriate antidiuretic hormone secretion (siadh).

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

takeda pharma a/s - brentuksimaba vedotīns - lymphoma, non-hodgkin; hodgkin disease - antineoplastiski līdzekļi - hodgkin lymphomaadcetris is indicated for adult patients with previously untreated cd30+ stage iv hodgkin lymphoma (hl) in combination with doxorubicin, vinblastine and dacarbazine (avd). adcetris is indicated for the treatment of adult patients with cd30+ hl at increased risk of relapse or progression following autologous stem cell transplant (asct). adcetris ir norādīts ārstēšanai pieaugušiem pacientiem ar relapsed vai ugunsizturīgs cd30+ hodgkin limfomas (hl):pēc asct, orfollowing vismaz divas pirms terapiju, kad asct vai multi-agent ķīmijterapiju nav iespēja ārstēties. sistēmisko anaplastic liels šūnu lymphomaadcetris kombinācijā ar ciklofosfamīdu, doksorubicīna un prednizonu (tec) ir indicēts pieaugušiem pacientiem ar iepriekš neārstētiem sistēmisko anaplastic liels šūnu limfomas (salcl). adcetris ir norādīts ārstēšanai pieaugušiem pacientiem ar relapsed vai ugunsizturīgs salcl. Ādas t šūnu lymphomaadcetris ir norādīts ārstēšanai pieaugušiem pacientiem ar cd30+ ādas t šūnu limfomas (ctcl) pēc vismaz 1 pirms sistēmiskā terapija.